Clinical trials: Why every medicine you take exists because strangers volunteered to test it first
Clinical trials: The volunteers testing tomorrow's medicines on their bodies today
Sarah held the consent form in her hands, reading it for the third time.
She had breast cancer. Standard treatment wasn’t working. Her oncologist suggested enrolling in a Phase II clinical trial testing a new drug that showed promise in early studies.
“I won’t lie,” her doctor said. “We don’t know yet if this works better than what we have. That’s why we’re testing it. But you’d be helping us find out—for yourself and for everyone who comes after you.”
Sarah signed. Six months later, scans showed her tumor shrinking. The drug eventually got approved and is now saving thousands of lives annually.
Every medicine in every pharmacy exists because people like Sarah volunteered to test it first. That’s what clinical trials are—research studies where real people test new treatments so we can learn what works and what doesn’t.
The Testing Pipeline Nobody Thinks About
Before any drug reaches your medicine cabinet, it goes through years of rigorous testing.
Scientists start in laboratories with cells and animals. If results look promising, they move to human testing—clinical trials. This is where theory meets reality.
There are four phases, each designed to answer specific questions:
Phase I tests new drugs for the first time in a small group of people—often 20-80 volunteers. The main questions: Is it safe? What’s the right dosage? What side effects occur?
These are the riskiest trials. Volunteers are essentially human guinea pigs testing something never before given to people. They’re closely monitored, often staying in research facilities for observation.
Phase II expands testing to a larger group—typically a few hundred people. The drug has been deemed safe enough in Phase I. Now researchers monitor for adverse effects in more diverse bodies and start gathering evidence about whether it actually works.
Phase III involves large populations across different regions and countries—often thousands of participants. This is typically the final step before regulatory approval. Researchers compare the new treatment to existing standards, looking for benefits and risks that might only appear in large, diverse populations.
Phase IV happens after a treatment gets approved. Now it’s being used in the wider population, and researchers continue monitoring for long-term effects or rare side effects that didn’t show up in earlier trials.
The Volunteers Making Medicine Possible
Dr. Chen runs clinical trials at a major research hospital. She’s enrolled thousands of participants over her career.
“People participate for different reasons,” she told me. “Some have conditions without good treatment options and hope the trial helps them. Others are healthy volunteers who want to contribute to medical progress. Many participate because someone they loved died from a disease they’re helping research.”
I met James, a healthy 28-year-old who’s participated in five Phase I trials. His motivation is simple: “I’m young, healthy, and I get paid. Plus I’m helping develop medicines. It feels good knowing that whatever data they collect from me might help create the next life-saving drug.”
People of all ages participate in clinical trials, including children. Pediatric trials are particularly important because children’s bodies process drugs differently than adults—we can’t just assume a drug safe for adults is safe for kids.
The Global Inequality Problem
Here’s where things get complicated: most clinical trials happen in wealthy countries while most diseases burden poor countries.
A drug might be tested extensively in North America and Europe but barely at all in Africa or Southeast Asia. This creates problems because genetics, environment, diet, and other factors can affect how drugs work.
Dr. Okonjo in Nigeria described her frustration: “We see new treatments approved based on trials conducted entirely in Western populations. Then we prescribe them to our patients, hoping they work similarly. Sometimes they do. Sometimes they don’t. We have limited data for our population.”
The 2022 World Health Assembly recognized this problem, passing a resolution to strengthen clinical trials globally. The focus: supporting low and middle-income countries to build capacity for conducting high-quality trials locally.
This means training researchers, establishing ethical review boards, creating infrastructure for data collection, and ensuring regulatory oversight meets international standards.
The Ethics That Must Never Budge
Clinical trials must be ethical. Period.
Participants must provide informed consent—meaning they fully understand what they’re agreeing to, including potential risks. They can withdraw anytime without penalty. Their data must be kept confidential.
Trials must be reviewed and approved by ethics committees before starting. These committees evaluate whether the research question is important enough to justify asking people to participate, whether risks are minimized and reasonable, and whether vulnerable populations are protected.
But history shows us how badly things can go wrong when ethics are ignored. The infamous Tuskegee study deliberately withheld treatment from Black men with syphilis. Nazi experiments on concentration camp prisoners violated every principle of human dignity.
These atrocities led to international agreements on research ethics—principles that now govern all legitimate clinical trials worldwide.
Dr. Martinez, who chairs an ethics review board, emphasized the gravity: “Every time I review a trial protocol, I ask myself: Would I be comfortable if my family member enrolled? If the answer is no, we don’t approve it.”
The Massive Registry Gap
Until recently, finding information about clinical trials was nearly impossible.
Researchers might register trials with their country’s system, but data varied wildly. Some trials never got registered at all. Results often went unpublished, especially negative results.
This created huge problems. Researchers wasted resources duplicating studies already done. Doctors couldn’t find information about trials their patients might benefit from. Failed trials remained hidden, meaning others repeated the same mistakes.
WHO’s International Clinical Trials Registry Platform (ICTRP) addresses this by linking registries globally. Now there’s a single access point where anyone can search for trials worldwide.
The platform aims to make all clinical trial information publicly available. Patients can find trials they might enroll in. Researchers can see what’s already being studied. Families can access data about treatments.
This transparency benefits everyone except those who prefer keeping negative results hidden.
The Missing Voices
For years, clinical trials systematically excluded certain populations.
Pregnant women? Almost always excluded. Breastfeeding mothers? Usually excluded. The reasoning was protecting the fetus or baby.
But here’s the problem: pregnant and breastfeeding women get sick too. They need medicines. And excluding them from trials means prescribing drugs with almost no data on safety or efficacy during pregnancy.
Dr. Kim, a maternal-fetal medicine specialist, explained the bind: “A pregnant woman gets sick. I need to prescribe medication. But there’s no trial data because pregnant women were excluded from research. I’m essentially conducting an uncontrolled experiment on my patient.”
WHO now emphasizes including pregnant and breastfeeding women in appropriate trials, with proper safeguards and monitoring.
Similar exclusions affected older adults, people with multiple conditions, racial and ethnic minorities. The result was medicines tested primarily on young, healthy, white men—then prescribed to everyone else.
Strengthening trial diversity means ensuring participants reflect the actual populations who’ll use the treatments.
Why This Matters to You
Every medicine you’ve ever taken went through this process.
The antibiotic that cured your child’s ear infection? Clinical trials proved it worked. The vaccine protecting you from disease? Tested in trials across multiple continents. The pain medication you take for headaches? Volunteers tested it first.
When trials are done well, we get safe, effective treatments with clear evidence. When they’re rushed or poorly designed, we get disasters—drugs that seemed promising but caused harm, vaccines that didn’t work as hoped, treatments that helped some populations but not others.
The COVID-19 pandemic showed both the power and challenges of clinical trials. Vaccines were developed, tested, and approved at unprecedented speed through massive global trials involving hundreds of thousands of volunteers. It saved millions of lives.
But it also exposed inequalities—wealthy countries got vaccine trials and access first while poorer countries waited.
Moving Forward
WHO’s new Global Action Plan for Clinical Trial Ecosystem Strengthening outlines what needs to happen.
Strengthen international collaboration, especially for multi-country trials and rapid coordination during emergencies. Build capacity in low and middle-income countries to conduct trials meeting international standards. Ensure equity—that all populations are included appropriately and benefit from research.
Improve trial quality and transparency through better registration, data sharing, and publication of results—positive and negative.
Sarah, the breast cancer patient from the beginning, finished her trial successfully. The drug worked for her and many others.
“I’m grateful I had the option to participate,” she said. “But I know millions of people worldwide don’t have access to cutting-edge trials. That needs to change. Everyone deserves a chance at tomorrow’s medicine, not just those in wealthy countries.”
Every pill you swallow exists because volunteers tested it. The question is whether we’ll ensure that system works fairly for everyone, everywhere.
For more information:
- WHO Clinical Trials Resources
- International Clinical Trials Registry Platform
- Global Action Plan for Clinical Trials
- Clinical Trials Best Practices Guidance
Disclaimer: This article is an adaptation of publicly available information from WHO’s Clinical trials
health topic page (WHO, Geneva. Licence: CC BYNC-SA 3.0 IGO). WHO is not responsible for the
content or accuracy of this adaptation. This content is for informational and educational purposes
only and does not constitute medical advice. ObserverVoice.com is a news and information platform
— not a healthcare provider.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
